Roquinimex

DB11366

small molecule investigational

Deskripsi

Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

Struktur Molekul 2D

Berat 308.337
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

48 Data
Pamidronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Pamidronic acid.
Zoledronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Zoledronic acid.
Alendronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Alendronic acid.
Ibandronate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Ibandronate.
Clodronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Clodronic acid.
Risedronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Risedronic acid.
Etidronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Etidronic acid.
Tiludronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Tiludronic acid.
Incadronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Incadronic acid.
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Roquinimex.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Roquinimex.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Roquinimex.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Roquinimex.
Lidocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Quinisocaine.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Roquinimex.
Ambroxol The risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Roquinimex is combined with Etrasimod.

Target Protein

Interleukin-2 IL2

Referensi & Sumber

Synthesis reference: E. Eriksoo et al., EP 59698; eidem, U.S. Patent 4,738,971 (1982, 1988 both to AB Leo).

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul